GSK’s Gepotidacin shows promise as new treatment for gonorrhoea amid rising resistance

GSK plc unveiled encouraging results from its pivotal Eagle-1 phase 3 trial for gepotidacin, a potential breakthrough oral antibiotic for uncomplicated urogenital gonorrhoea (GC) in adolescents and adults.